PCM
Penserra Capital Management Portfolio holdings
AUM
$7.17B
1-Year Return
49.58%
This Quarter Return
+33.7%
1 Year Return
+49.58%
3 Year Return
+118.16%
5 Year Return
+229.83%
10 Year Return
–
AUM
$4.23B
AUM Growth
+$1.6B
(+61%)
Cap. Flow
+$935M
Cap. Flow
% of AUM
22.08%
Top 10 Holdings %
Top 10 Hldgs %
21.32%
Holding
1,174
New
230
Increased
606
Reduced
167
Closed
168
Top Buys
| 1 |
KE Holdings
BEKE
|
+$78.6M |
| 2 |
Lufax Holding
LU
|
+$56.6M |
| 3 |
Groupon
GRPN
|
+$50.3M |
| 4 |
JD.com
JD
|
+$43.7M |
| 5 |
Lands' End
LE
|
+$36.7M |
Top Sells
| 1 |
JMIA
Jumia Technologies
JMIA
|
+$35.9M |
| 2 |
Peloton Interactive
PTON
|
+$31.3M |
| 3 |
Match Group
MTCH
|
+$23.5M |
| 4 |
Fiverr
FVRR
|
+$16.6M |
| 5 |
Stitch Fix
SFIX
|
+$14.7M |
Sector Composition
| 1 | Consumer Discretionary | 35.59% |
| 2 | Technology | 23.48% |
| 3 | Communication Services | 13.86% |
| 4 | Real Estate | 4.37% |
| 5 | Industrials | 4.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
726
MongoDB
MDB
$26.9B
| $40K | ﹤0.01% |
+114
| New | +$40K |
|
727
Madrigal Pharmaceuticals
MDGL
$10.1B
| $40K | ﹤0.01% |
+360
| New | +$40K |
|
728
Nasdaq
NDAQ
$54.4B
| $40K | ﹤0.01% |
915
-45,066
| -98% | -$1.97M |
|
729
Replimune Group
REPL
$454M
| $40K | ﹤0.01% |
+1,055
| New | +$40K |
|
|
KSU
730
DELISTED
Kansas City Southern
KSU
| $40K | ﹤0.01% |
196
+26
| +15% | +$5.31K |
|
731
CDW
CDW
$22B
| $39K | ﹤0.01% |
300
+62
| +26% | +$8.06K |
|
732
Regenxbio
RGNX
$479M
| $39K | ﹤0.01% |
860
+540
| +169% | +$24.5K |
|
733
Dover
DOV
$24.4B
| $38K | ﹤0.01% |
304
+66
| +28% | +$8.25K |
|
734
W.W. Grainger
GWW
$47.7B
| $38K | ﹤0.01% |
95
+27
| +40% | +$10.8K |
|
|
ENDP
735
DELISTED
Endo International plc
ENDP
| $38K | ﹤0.01% |
5,345
+3,385
| +173% | +$24.1K |
|
736
Scholar Rock
SRRK
$3.04B
| $37K | ﹤0.01% |
770
+514
| +201% | +$24.7K |
|
737
Broadridge
BR
$29.7B
| $37K | ﹤0.01% |
243
+39
| +19% | +$5.94K |
|
738
HUTCHMED
HCM
$2.76B
| $37K | ﹤0.01% |
1,180
+762
| +182% | +$23.9K |
|
739
Keros Therapeutics
KROS
$628M
| $37K | ﹤0.01% |
+530
| New | +$37K |
|
740
uniQure
QURE
$960M
| $37K | ﹤0.01% |
1,025
+647
| +171% | +$23.4K |
|
|
DRNA
741
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $37K | ﹤0.01% |
1,720
+1,082
| +170% | +$23.3K |
|
742
Hartford Financial Services
HIG
$36.7B
| $37K | ﹤0.01% |
758
+180
| +31% | +$8.79K |
|
743
Ligand Pharmaceuticals
LGND
$3.22B
| $36K | ﹤0.01% |
593
+372
| +168% | +$22.6K |
|
744
Tyler Technologies
TYL
$24.5B
| $36K | ﹤0.01% |
84
+16
| +24% | +$6.86K |
|
745
Atara Biotherapeutics
ATRA
$85.5M
| $35K | ﹤0.01% |
71
+46
| +184% | +$22.7K |
|
746
HubSpot
HUBS
$26.3B
| $35K | ﹤0.01% |
+90
| New | +$35K |
|
747
United Rentals
URI
$62.4B
| $35K | ﹤0.01% |
151
+15
| +11% | +$3.48K |
|
748
Ally Financial
ALLY
$12.7B
| $34K | ﹤0.01% |
983
+371
| +61% | +$12.8K |
|
749
Inovio Pharmaceuticals
INO
$146M
| $34K | ﹤0.01% |
329
+210
| +176% | +$21.7K |
|
750
Myriad Genetics
MYGN
$643M
| $34K | ﹤0.01% |
1,750
+1,112
| +174% | +$21.6K |
|